biostudies-literatureRamondetta LMBlanton-Davis Ovarian Cancer Research ProgramNCI NIH HHSFrank McGraw Memorial Chair in Cancer ResearchNational Institutes of Health524-530https://www.ebi.ac.uk/biostudies/studies/S-EPMC6867685biostudies-literatureUnknown154(3)<h4>Objective</h4>To determine the feasibility of pharmacologic beta-adrenergic blockade in women with newly diagnosed stage II-IV epithelial ovarian cancer (EOC) throughout primary treatment.<h4>Methods</h4>Patients initiated propranolol prior to beginning chemotherapy or surgery. Feasibility was assessed as proportion able to complete 6 chemotherapy cycles while on adrenergic suppression. Descriptive statistics summarized surveys, and paired changes were analyzed using signed rank tests. Random-intercept Tobit models examined immune response.<h4>Results</h4>Median age was 59.9; 88.5% were stage IIIC/IV; and 38.5% underwent primary debulking. Thirty-two patients were enrolled; 3 excluded because they never took propranolol; an additional 3 didn't meet inclusion criteria, leaving 26 evaluaGynecologic oncologyProspective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.PMC6867685P30 CA016672CPRIT RP210214P50 CA217685Sood AKFleming NArevalo JMGHu WColeman RLThaker PHSahai SKRamondetta LMSun YUrbauer DLCole SWWestin SNDizon TRamirez PTChisholm GBNick AMfalseProspective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.<h4>Objective</h4>To determine the feasibility of pharmacologic beta-adrenergic blockade in women with newly diagnosed stage II-IV epithelial ovarian cancer (EOC) throughout primary treatment.<h4>Methods</h4>Patients initiated propranolol prior to beginning chemotherapy or surgery. Feasibility was assessed as proportion able to complete 6 chemotherapy cycles while on adrenergic suppression. Descriptive statistics summarized surveys, and paired changes were analyzed using signed rank tests. Random-intercept Tobit models examined immune response.<h4>Results</h4>Median age was 59.9; 88.5% were stage IIIC/IV; and 38.5% underwent primary debulking. Thirty-two patients were enrolled; 3 excluded because they never took propranolol; an additional 3 didn't meet inclusion criteria, leaving 26 evalua2019-01-01T00:00:00Z2019 Sep2025-06-01T12:00:33.757Z2020-09-05T07:03:38ZS-EPMC68676853135305310.1016/j.ygyno.2019.07.004